593 related articles for article (PubMed ID: 33577677)
1. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs.
Hou G; Zhao X; Li L; Yang Q; Liu X; Huang C; Lu R; Chen R; Wang Y; Jiang B; Yu J
Nucleic Acids Res; 2021 Mar; 49(5):2859-2877. PubMed ID: 33577677
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation of the m6A reader YTHDF2 by PIAS1 promotes viral RNA decay to restrict EBV replication.
Sugiokto FG; Saiada F; Zhang K; Li R
mBio; 2024 Feb; 15(2):e0316823. PubMed ID: 38236021
[TBL] [Abstract][Full Text] [Related]
3. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
4. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
Du Y; Hou G; Zhang H; Dou J; He J; Guo Y; Li L; Chen R; Wang Y; Deng R; Huang J; Jiang B; Xu M; Cheng J; Chen GQ; Zhao X; Yu J
Nucleic Acids Res; 2018 Jun; 46(10):5195-5208. PubMed ID: 29506078
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
[TBL] [Abstract][Full Text] [Related]
6. YTHDF2 protein stabilization by the deubiquitinase OTUB1 promotes prostate cancer cell proliferation via PRSS8 mRNA degradation.
Zhao X; Lv S; Li N; Zou Q; Sun L; Song T
J Biol Chem; 2024 Apr; 300(4):107152. PubMed ID: 38462165
[TBL] [Abstract][Full Text] [Related]
7. SUMOylation of the m6A reader YTHDF2 by PIAS1 promotes viral RNA decay to restrict EBV replication.
Sugiokto FG; Saiada F; Zhang K; Li R
bioRxiv; 2023 Aug; ():. PubMed ID: 37609256
[TBL] [Abstract][Full Text] [Related]
8. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
[TBL] [Abstract][Full Text] [Related]
9. N6-methyladenosine-dependent regulation of messenger RNA stability.
Wang X; Lu Z; Gomez A; Hon GC; Yue Y; Han D; Fu Y; Parisien M; Dai Q; Jia G; Ren B; Pan T; He C
Nature; 2014 Jan; 505(7481):117-20. PubMed ID: 24284625
[TBL] [Abstract][Full Text] [Related]
10. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3β.
Li H; Zhang N; Jiao X; Wang C; Sun W; He Y; Ren G; Huang S; Li M; Chang Y; Jin Z; Xie Q; Zhang X; Huang H; Jin H
Clin Transl Med; 2021 Oct; 11(10):e602. PubMed ID: 34709763
[TBL] [Abstract][Full Text] [Related]
12. m6A Reader YTHDF2 Regulates LPS-Induced Inflammatory Response.
Yu R; Li Q; Feng Z; Cai L; Xu Q
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875984
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-145 Modulates
Yang Z; Li J; Feng G; Gao S; Wang Y; Zhang S; Liu Y; Ye L; Li Y; Zhang X
J Biol Chem; 2017 Mar; 292(9):3614-3623. PubMed ID: 28104805
[No Abstract] [Full Text] [Related]
14. Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts.
Imam H; Kim GW; Mir SA; Khan M; Siddiqui A
PLoS Pathog; 2020 Feb; 16(2):e1008338. PubMed ID: 32059034
[TBL] [Abstract][Full Text] [Related]
15. Understanding YTHDF2-mediated mRNA degradation by m6A-BERT-Deg.
Zhang TH; Jo S; Zhang M; Wang K; Gao SJ; Huang Y
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38622358
[TBL] [Abstract][Full Text] [Related]
16. The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C; van de Lagemaat LN; Lawson H; Tavosanis A; Paris J; Campos J; Wotherspoon D; Durko J; Sarapuu A; Choe J; Ivanova I; Krause DS; von Kriegsheim A; Much C; Morgan M; Gregory RI; Mead AJ; O'Carroll D; Kranc KR
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33156926
[TBL] [Abstract][Full Text] [Related]
17. YTHDF2 destabilizes m
Heck AM; Russo J; Wilusz J; Nishimura EO; Wilusz CJ
RNA; 2020 Jun; 26(6):739-755. PubMed ID: 32169943
[No Abstract] [Full Text] [Related]
18. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
Hou J; Zhang H; Liu J; Zhao Z; Wang J; Lu Z; Hu B; Zhou J; Zhao Z; Feng M; Zhang H; Shen B; Huang X; Sun B; Smyth MJ; He C; Xia Q
Mol Cancer; 2019 Nov; 18(1):163. PubMed ID: 31735169
[TBL] [Abstract][Full Text] [Related]
19. FBW7 suppresses ovarian cancer development by targeting the N
Xu F; Li J; Ni M; Cheng J; Zhao H; Wang S; Zhou X; Wu X
Mol Cancer; 2021 Mar; 20(1):45. PubMed ID: 33658012
[TBL] [Abstract][Full Text] [Related]
20. YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators.
Fei Q; Zou Z; Roundtree IA; Sun HL; He C
PLoS Biol; 2020 Apr; 18(4):e3000664. PubMed ID: 32267835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
